BIOMAT Database Logo BIOMAT Database Logo

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. 1998

D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Departments of Medicinal Chemistry, Cancer Research, Vascular, Cardiac Diseases, Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA. bosched@war.wyeth.com

Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (1) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of 1 with a 4-(N,N-diethylaminoethoxy)phenylamino group yielded 2a, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogues that retained potency, including derivatives that were biased toward inhibition of the TK activity of PDGFr. Analogues of 2a with a 3-thiophene or an unsubstituted phenyl group at C-6 were the most potent inhibitors. Compound 54, which had IC50 values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, respectively, was active in a variety of PDGF-dependent cellular assays and blocked the in vivo growth of three PDGF-dependent tumor lines.

UI MeSH Term Description Entries
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
April 1996, Journal of medicinal chemistry,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists.
October 2007, Bioorganic & medicinal chemistry letters,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
September 1995, Journal of medicinal chemistry,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
October 2012, Bioorganic & medicinal chemistry letters,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.
July 1997, Journal of medicinal chemistry,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
December 2018, Bioorganic chemistry,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors.
May 2010, Organic & biomolecular chemistry,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
November 1997, Journal of medicinal chemistry,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
January 2009, Bioorganic & medicinal chemistry letters,
D H Boschelli, and Z Wu, and S R Klutchko, and H D Showalter, and J M Hamby, and G H Lu, and T C Major, and T K Dahring, and B Batley, and R L Panek, and J Keiser, and B G Hartl, and A J Kraker, and W D Klohs, and B J Roberts, and S Patmore, and W L Elliott, and R Steinkampf, and L A Bradford, and H Hallak, and A M Doherty
Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
February 2021, European journal of medicinal chemistry,
Copied contents to your clipboard!